Ascendis Pharma (ADR)
Builds and commercializes rare-endocrinology medicines through the TransCon prodrug platform.
Something off on this page? Send us feedback.
Profile
Develops and commercializes TransCon-based rare-endocrinology medicines, led by SKYTROFA, YORVIPATH, and YUVIWEL. Direct sales focus on the United States and Europe, with partners covering selected geographies and therapeutic areas; the business depends on regulatory outcomes, a limited product set, and third-party manufacturing and distribution.
Develops and commercializes rare-endocrinology medicines built on the TransCon long-acting prodrug platform. The direct portfolio comprises SKYTROFA for growth hormone deficiency, YORVIPATH for adult hypoparathyroidism, and YUVIWEL for pediatric achondroplasia, all managed within one business unit.
Retains direct commercial focus in the United States and Europe while using partners in Greater China and selected therapeutic areas or geographies. Applying one platform across the portfolio has carried the business from clinical development into a three-brand commercial operation, with YORVIPATH providing the largest share of recent product revenue.
Depends on regulatory outcomes, commercialization of a limited product set, and third-party manufacturing, distribution, and services. YUVIWEL's accelerated approval may depend on confirmatory verification of clinical benefit.
Company facts
Key statistics
Year to date +16.2% · Average volume (30d) 475.7K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 27, 2026 | H.C. Wainwright | Initiate | Buy | $345 | |
| Aug 18, 2026 | BMO Capital | Initiate | Outperform | $319 | |
| Aug 14, 2026 | RBC Capital | Reiterate | Outperform | $280 | $290 |
| Aug 14, 2026 | Barclays | Reiterate | Overweight | $345 | $329 |
| Aug 13, 2026 | Jefferies | Reiterate | Buy | $262 | $333 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | $1.71 | $3.29 | +92.4% | $376.8M | $387.5M | +2.8% | −3.61% |
| May 7, 2026Q1 FY26 | $0.21 | $0.32 | +52.4% | $363.2M | $335.0M | −7.8% | −3.04% |
| Feb 11, 2026Q4 FY25 | −$0.06 | −$0.64 | −966.7% | $292.3M | $344.8M | +18.0% | −1.53% |
| Nov 12, 2025Q3 FY25 | −$0.41 | −$1.17 | −185.4% | $302.6M | $250.2M | −17.3% | +3.63% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $117.0M | $183.1M | $247.5M | $284.1M | $290.4M | $399.6M | |
| Gross profit | $96.7M | $146.7M | $221.6M | $252.6M | $265.4M | $362.2M | |
| Operating income | −$120.7M | −$61.4M | $12.7M | $11.4M | $29.2M | $73.5M | |
| Net income | −$109.6M | −$45.0M | −$70.7M | −$38.5M | $741.2M | $243.8M | |
| Diluted EPS | −$1.83 | −$0.95 | −$1.16 | −$0.63 | $11.48 | $3.57 | |
| Gross margin | 82.6% | 80.1% | 89.5% | 88.9% | 91.4% | 90.6% | |
| Operating margin | -103.2% | -33.5% | 5.1% | 4.0% | 10.1% | 18.4% |
Fiscal years (4-quarter sums)FY21 $9.0M · FY22 $59.3M · FY23 $309.0M · FY24 $421.3M · FY25 $831.7M
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $940.8M · Total debt $521.3M · Total assets $2.65B · Shareholders' equity $1.66B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 62.11M · Float 61.56M · 99.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 10.28M | 16.55% | 13F | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 6.75M | 10.88% | 13F | Aug 14, 2026 |
| Avoro Capital Advisors LLC | 5.11M | 8.23% | 13F | Aug 14, 2026 |
| Westfield Capital Management Co LP | 4.80M | 7.73% | 13F | Aug 12, 2026 |
| Janus Henderson Group PLC | 3.72M | 6.00% | 13G | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 14, 2026 | Jean Jacques Bienaime | director | +2,000 | $246.33 |
| Jun 2, 2026 | Scott Thomas Smith | officer: EVP & Chief Financial Officer | +100 | $219.00 |
| May 29, 2026 | Scott Thomas Smith | officer: EVP & Chief Financial Officer | +250 | $223.32 |
| May 29, 2026 | Jean Jacques Bienaime | director | +500 | $223.12 |
| May 26, 2026 | Jean Jacques Bienaime | director | +400 | $237.80 |
Peers
- BioMarin
Approved achondroplasia incumbent with daily VOXZOGO
- AstraZeneca (ADR)
Late-stage PTH-receptor challenger in adult hypoparathyroidism
- Novo Nordisk (ADR)
Weekly and daily growth-hormone rival across pediatric and adult GHD
- M.B.X. Biosciences
Once-weekly PTH prodrug advancing toward Phase 3
- Pfizer
Weekly pediatric and daily growth-hormone franchise
- BridgeBio Pharma
Late-stage oral FGFR3 inhibitor for achondroplasia
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Ascendis Pharma (ADR) | $247.91 | 0.00% | $15.40B | 18.7 | 31.9 | 12.6 | +108.2% |
| BioMarin | $64.67 | +0.02% | $12.50B | 165.8 | 10.4 | 3.7 | +19.9% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| M.B.X. Biosciences | $63.00 | +0.02% | $3.00B | — | — | — | — |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| BridgeBio Pharma | $76.60 | +0.03% | $15.00B | — | — | 21.7 | +120.4% |
| Median | 30.7 | 12.8 | 4.0 | +6.4% |